Business Wire

Shippeo Introduces Carbon Visibility and Brings Powerful New Features to Ocean and Road Visibility

9.5.2022 13:28:00 EEST | Business Wire | Press release

Share

Shippeo, a leading provider of global and multimodal shipment visibility, today announced new products and major platform enhancements, as part of their feature-packed 2022 Spring platform release. The updates focus on customer satisfaction, new innovations, performance, and meeting evolving market needs. A new CO2 emissions calculator provides critical information on carbon emissions and other greenhouse gasses from supply chain transport and distribution for shippers, logistics service providers and carriers. Container tracking using Shippeo’s Ocean Visibility solution is now faster and easier with a new user experience and powerful monitoring capabilities. In addition, timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for the company’s market-leading Road Visibility product. Finally with the migration to Google Cloud and Snowflake, significant performance and scalability upgrades are added to the Shippeo platform.

“Our latest Spring platform release is packed full of new features and capabilities for customers,” explains Anand Medepalli, Chief Product Officer at Shippeo, “including a completely new Carbon Visibility offering for accurately calculating CO2 and other greenhouse gas emissions at the shipment level, as well as major enhancements to our Ocean and Road visibility solutions. We are evolving our platform to not only meet the needs of our customers today, but also to solve tomorrow’s supply chain problems. This is the first release in a new twice-yearly Spring and Autumn Shippeo platform release cycle, representing a shift to more regular and regimented platform updates. This reliability and momentum will help us to keep ahead and continue to offer the most innovative real-time visibility platform experience for users, more powerful capabilities to increase productivity, and higher data quality to improve ROI for our customers.”

Accurate, consolidated CO2 emissions monitoring for shippers and carriers
Carbon Visibility offers shippers and logistics service providers a consolidated view of CO2 emissions for upstream and downstream transport and distribution activities in one place, bringing a number of new capabilities to help companies monitor progress towards sustainability objectives.

Carriers also benefit from the new Carbon Visibility offering, allowing them to avoid the time consuming manual work that they are faced with today to calculate emissions on behalf of their clients. Carriers can now use Shippeo to instantly generate CO2 emission reports, which should allow them to more easily allocate CO2 emissions from a single vehicle to multiple customers in LTL/groupage scenarios based on their business rules.

The Shippeo Carbon calculator follows the GLEC framework and is compliant with EN 16258 and GHG protocol.

Advanced container tracking over ocean
Major enhancements to Ocean Visibility will help supply chain and transport managers track and manage container shipments more productively, with new features and a revamped user experience, including:

  • More detailed container event information with new AIS-based milestones and precise geofencing
  • A revamped order detail page displaying all relevant container tracking information
  • Ability to identify deviations from status information provided by ocean carriers
  • An updated global map providing a holistic view of ocean shipments, by vessel or individual container
  • New filters making searching for containers easier
  • Higher overall data quality with inputs from new data sources

Road tracking enhancements
Timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for Road Visibility , offering customers an even more powerful over-the-road shipment tracking solution.

  • ETA accuracy improves 32% thanks to AI/ML algorithm advancements, upgraded Dataiku ML Ops platform infrastructure and data science methodology advancements
  • Shuttle flow tracking enables better differentiation between shipments within multiple back-and-forth tours for more accurate departure and arrival times
  • Quality Newsletters notify users of data tracking rates and provides steps for improving tracking quality
  • Improved visibility and readability of information, with new tagged events and links between map and timeline views

Infrastructure improvements to boost data quality and user experience
Shippeo’s platform has been migrated to Google Cloud Platform in its entirety, representing a major improvement in infrastructure. The shift ensures significant scalability, performance and localization capabilities along with enhanced security for customers.

Alongside the platform feature additions and enhancements, Shippeo has also continued to double-down on higher data quality, an area in which the company consistently leads the market. Continued investment of significant capital into R&D aims to advance the platform’s AI/ML capabilities even further.

To that point, the data warehouse powering Shippeo Insights is now migrated to Snowflake, a state-of-the-art high-performance analytics database that has managed to reduce Shippeo dashboard loading times by 50% on average and up to 90% for large customers.

About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com

LinkedIn, Facebook, Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Europe: Andrea Krug, Krug Communications Ltd, Tel. +44 (0)7740 245 867, email: andrea@krugcomms.com

North America: Carol Kraeutler Lerner, CKL Communications, Tel. +1 (201) 602-7572, email: ckl.communications@gmail.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye